Skip to main content

Semax Peptide: Benefits, side effects, dosage details, and how it works

We break down the science behind this nootropic peptide so you can better understand its therapeutic potential.

by
Last updated: Aug 15th, 2025
Semax Peptide Upper

Photo by Innerbody Research

You could probably guess why nootropics, or “smart drugs,” constitute such a popular health market. We could all do with a little more brain power, after all.

Better brain function is exactly what the peptide Semax was made to deliver. Developed in Russia in the 1980s, Semax stands out as a promising therapy for cerebral health and neurodegenerative disorders. But because widespread pharmaceutical use and the relevant research are largely limited to its native region, reliable information about its therapeutic applications is somewhat scarce outside of Russia and Eastern Europe. Apart from a relatively light body of English-language scientific literature, a lot of the reportage on Semax comes from niche influencers and online vendors with questionable pedigrees.

So we’ve written this guide with the goal of unifying key takeaways from the most reliable research on Semax to date. By the end of it, you should have the clearest possible understanding of Semax’s potential benefits, risks, and availability.

Jump to

Jump to:

Why you should trust us

Over the past two decades, Innerbody Research has helped tens of millions of readers make more informed decisions about staying healthy and living healthier lifestyles.

This Semax guide is part of our ongoing series on therapeutic peptides, an endeavor to which we’ve devoted over 1,000 hours of research and writing so far. As with all of our guides, we familiarized ourselves with Semax through the available scientific literature. Where pertinent, we cross-referenced the studies and reviews on Semax with supplemental research on associated factors, such as the role of the natural peptide that Semax mimics and the efficacy of the nasal route of administration.

Additionally, like all health-related content on this website, this guide was thoroughly vetted by one or more members of our Medical Review Board for accuracy and will continue to be monitored for updates by our editorial team.

What is Semax?

Semax is a peptide analog, or a synthetic and modified version of a naturally occurring peptide. It specifically mimics a fragment of the pituitary chemical adrenocorticotropic hormone (ACTH).

While ACTH is best known for its endocrine activity (triggering the release of other hormones, namely cortisol and androgens), it also has neurotrophic effects (i.e., it supports the development and survival of neurons). However, since Semax mimics only a fragment of ACTH, not the whole molecule, it doesn’t behave exactly the same. According to the Alzheimer’s Drug Discovery Foundation (ADDF), Semax delivers the neurotrophic effects of ACTH but not the hormonal/endocrine ones, so it circumvents the onset of symptoms associated with overactive ACTH secretion (e.g., upper-body obesity, “buffalo” hump, high blood pressure).

Routes of administration

Semax can be administered effectively via injection or intranasal (through-the-nose) administration. This is a point of differentiation from many other therapeutic peptides, which are often less effective through non-injectable routes because their molecules are too large to pass reliably into the bloodstream.

Further going against the grain, Semax appears to be more effective when administered intranasally, at least in terms of its nootropic benefit. In a 2012 study published in Neuroscience and Behavioral Physiology, researchers found that intranasal Semax yielded a more pronounced improvement in learning in rodent subjects compared to intraperitoneal injection. The downside was that intranasal administration provided no analgesic (pain-relieving) action, which is one of Semax’s secondary therapeutic uses.

Primary therapeutic uses of Semax

Semax is a neuropeptide, a class of signaling molecules in the brain with numerous functions. In Russia and Eastern Europe, Semax’s primary uses are nootropic (cognition-enhancing), neuroprotective (brain-preserving), anxiolytic (anxiety-reducing), antidepressant (mood-improving), and immunomodulatory (immune system–modifying). Below, we discuss the literature that supports Semax’s applications in these areas:

As a nootropic

There’s no consensus as to Semax’s nootropic mechanisms of action. Some researchers have proposed that it increases either the circulation of monoamines such as dopamine and serotonin or the metabolism of acetylcholine, as demonstrated in rodent studies. These monoamines have distinct motivating actions that can lead to increased cognitive function: dopamine drives you to associate cognitive tasks with a sense of reward, while serotonin may help you look past the “aversive costs” (e.g., time and effort) that could discourage you from beginning a cognitive task.

Another potential mechanism behind Semax’s nootropic action is its modulation of brain-derived neurotrophic factor (BDNF), a protein described as a “key molecule involved in plastic changes related to learning and memory.” Again in rodent studies, Semax administration has significantly increased BDNF expression in the brain, suggesting that the peptide can help users adapt to new information and form new neural connections in response. Accordingly, Semax may even be a potential therapeutic agent for attention-deficit/hyperactivity disorder (ADHD).

As a neuroprotective agent

By increasing BDNF expression in the brain, Semax is also a promising agent against neurodegeneration, such as from disease, stroke, or aging. Indeed, BDNF depletion is associated with increased biomarkers for Alzheimer’s disease, poor stroke recovery, and senescent cognitive decline. Semax’s therapeutic potential to treat these conditions finds support in human trials, including a 1997 study that saw improved neurological function in patients with ischemia after Semax administration, as well as a 2018 study demonstrating increased brain activity (suggesting positive implications for people with Alzheimer’s and those recovering from stroke).

As an anxiolytic/antidepressant

With low BDNF also being linked to anxiety and depression, Semax can additionally be used to treat such mood conditions. A 2024 study of ACTH analogs in rodents showed that coadministration of Semax with another analog successfully reduced the severity of depressive symptoms and increased BDNF levels in the brain, while an earlier study from 2010 found that Semax normalized behavior in rats induced with anxiety and depression.

As an immunomodulator

In a paper for a 2017 study of Semax in rats, researchers claim that “the immune response is the process most markedly affected by the peptide” owing to its ability to enhance the antigen presentation signaling pathway, influence the synthesis of immunoglobulins, and stimulate the interferon-signaling pathways. What that means, respectively, is that Semax helps (a) trigger immune responses, (b) create antibodies, and (c) strengthen resistance to viral infection.

Other benefits of Semax

Varying degrees of research indicate that Semax can provide some benefits outside of its primary therapeutic uses, namely with regard to:

  • Pain relief: A 2019 systematic review of Symax’s therapeutic uses proclaimed that “systemic administration of ACTH [from which Semax is derived] leads to an increase in the pain threshold,” and one of the studies referenced in the review saw decreased pain sensitivity in rats that received 0.015-0.5mg/kg intraperitoneal injections of Semax (i.e., directly into their abdominal cavities). It should be noted, however, that this analgesic effect was absent in subjects who received the peptide intranasally, and Semax prescribed to a human isn’t likely to be administered via direct injection into the peritoneum.
  • Improved cardiovascular health: In another study with intraperitoneal injection, rats induced with myocardial infarction exhibited preserved cellular architecture of the heart after Semax administration. Though there were no improvements in heart function, this finding suggests that Semax can alleviate the cardiovascular cell death that contributes to heart attacks and their complications.
  • Ulcer treatment: In a 2002 study in which rats were induced with stomach ulcers, Semax administration appeared to impart a “protective effect.” The researchers theorized this was due to increased blood flow to the gastric wall, stimulated by Semax.

Is Semax safe?

Safety information on Semax is meager outside of Russian-language scientific literature. The relatively little information we have comes from the ADDF and a 2022 review on Russian peptide biopharmaceuticals.

The ADDF report, published in 2020, notes “very little human evidence for potential side effects” despite “many preclinical trials,” and the authors presume a low side effect profile owing to Semax’s purportedly common use in Russia. Only two common adverse events are mentioned: discoloration of the nasal cavity with intranasal administration (approximately 10% of patients) and increased blood glucose levels in people with diabetes.

The 2022 review, largely in corroboration of the ADDF’s conclusion, states that Semax has “low toxicity,” is not habit-forming, and has no ill effects on:

  • Important bodily systems (e.g., central nervous and cardiovascular)
  • The metabolism of other drugs
  • Mental and physical stress resistance

Research-grade vs. pharmaceutical-grade Semax

Because Semax isn’t FDA-approved or even widely available outside of Russia and Eastern Europe, the curious Westerner may be tempted to purchase the peptide from an online retailer. We can’t promise you that any of these retailers are reputable, nor can we say whether they’re selling research-grade material or a pharmaceutical-grade medical product.

The odds are that if it’s available to you online, it’s research-grade. And you don’t want that. Research-grade peptides, which aren’t subject to the same quality controls as their pharmaceutical-grade counterparts, are for laboratory use only. Scientists can use them in experiments on cells and animal models, but they pose health risks in humans owing to their low purity levels. So, by injecting or inhaling research-grade Semax, you put yourself in danger of an immunogenetic reaction, in which your immune system perceives the peptide as a threat and mounts a potentially life-threatening anaphylaxis-like reaction against it.

Is it possible to find a proper pharmaceutical-grade Semax powder or nasal spray online? Maybe. If you find something that looks legitimate, you must carefully read the product page to be sure it isn’t meant only for the lab.

Also, as always, speak with your doctor before making any major health decisions, such as starting a peptide regimen.

What is it like to use Semax?

Without FDA approval or widespread use, Semax presents a minor mystery in terms of its use experience. But because Semax is a therapeutic peptide, it has a few things in common with other treatments in its class, and by consolidating findings from our research we can give you a broad yet accurate view of what to expect (should Semax become available to you).

Dosing and administration

Clinical studies in humans have administered Semax starting at doses of 1.2mg (intranasal) and ranging up to 1mg per kilogram (injectable). For medical use, the actual dosage can be much lower or higher depending on your desired health outcome.

Intranasal Semax will come in a ready-to-use vessel similar to, say, a Mucinex bottle, whereas the injectable version ought to come as a powder in a vial. To use injectable Semax, you must first reconstitute the powder with bacteriostatic water.

Though dosing frequencies may vary, a common protocol entails daily nasal administration or near-daily injections.

As with many therapeutic peptides, your protocol may require that you cycle your Semax use — several months of regular administration, followed by a one-month break. This pattern can help maintain efficacy by preventing drug tolerance.

Timeline of benefits

Some users report feeling cognitive enhancement benefits in as little as 30 minutes after Semax administration. Pain relief benefits may have a similarly rapid onset.

Any neuroprotective, immunomodulatory, and cardiovascular benefits are likely to take much longer to take effect — 2-4 weeks at least — and aren’t likely to be apparent to you in a daily-quality-of-life kind of way.

Storage

Reconstituted Semax powder ought to remain stable under refrigerated conditions (the U.K.’s National Institute for Biological Standards and Control recommends a storage temperature of 4°C, or 39°F).

Intranasal Semax can be stable at higher temperatures and doesn’t always need to be refrigerated — it may depend on the manufacturer. But at the very least, you should keep the bottle in a cool, dry environment under 10°C (50°F) and out of direct sunlight.

Who is Semax for (And not for)?

People who stand to gain the most benefit from Semax are those who have or at risk for:

  • Cognitive disorders: Semax’s nootropic properties may help increase one’s focus, memory, and capacity to learn.
  • Cognitive diseases or dysfunctions: As a neuroprotectant, Semax is often administered post-stroke to aid in recovery, as well as in cases of age-related cognitive decline.

Interestingly, despite its potential as an anxiolytic, Semax may not be indicated for people with anxiety disorders. In a 1996 study, researchers noted an “anxiogenic [anxiety-worsening] component in the spectrum of Semax’s behavioral effects” and suggested that the peptide would be optimally useful in people without elevated anxiety levels.

Other populations for whom Semax is contraindicated include people with diabetes (Semax may increase their blood sugar levels) and pregnant or breastfeeding women (there isn’t enough research to say whether Semax is safe for the developing fetus or child).

Where to find Semax

Currently, because Semax isn’t an FDA-approved drug, there are few to no reputable places to get it in the United States. While you can find online retailers selling Semax powder or spray, most of these right now are certain to be pushing research-grade products that (it must be reiterated) are not suitable for human use.

But the peptide landscape is ever-shifting, and Semax may one day become as readily accessible as the Ozempics and Mounjaros of the world. As this space evolves, we’ll make sure to update this guide accordingly.

38

Sources

Innerbody uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.

  1. Polaris Market Research. (2022). Nootropics market share, size, trends, industry analysis report, by form (Capsules/Tablets, powder, drinks, others); by distribution channel (Offline, online), by regions; Segment forecast, 2022-2030. Polaris Market Research.

  2. Cleveland Clinic. (2022). Adrenocorticotropic hormone (ACTH). Cleveland Clinic.

  3. Louis, J. C., Anglard, P., & Vincendon, G. (1986). Neurotropic action of adrenocorticotropic hormone. Presse Medicale, 15(4), 157-160.

  4. Alzheimer’s Drug Discovery Foundation. (2020). Semax. ADDF.

  5. Johns Hopkins Medicine. (n.d.). Overactive adrenal glands/Cushing's syndrome. Johns Hopkins Medicine.

  6. Brayden, D. (2020). Nanotechnology provides new methods for oral delivery of peptides. Research Outreach.

  7. Manchenko, D. M, et al. (2012). The nootropic and analgesic effects of Semax given via different routes. Neuroscience and Behavioral Physiology, 42(3), 264-270.

  8. Voronina, T. A. (2023). Cognitive impairment and nootropic drugs: Mechanism of action and spectrum of effects. Neurochemical Journal, 17, 180-188.

  9. Burbach, J. P. (2011). What are neuropeptides? Methods in Molecular Biology, 789, 1-36.

  10. Kolomin, T. A., et al. (2013). A new generation of drugs: synthetic peptides based on natural regulatory peptides. Neuroscience & Medicine, 4(4), 223-252.

  11. Eremin, K. O., et al. (2005). Semax, an ACTH (4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 30(12), 1493-500.

  12. Westbrook, A., & Braver, T. S. (2016). Dopamine does double duty in motivating cognitive effort. Neuron, 89(4), 695-710.

  13. Michely, J., et al. (2023). Boosting serotonin increases information gathering by reducing subjective cognitive costs. Journal of Neuroscience, 43(32) 5848-5855.

  14. Miranda, M., et al. (2019). Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain. Frontiers in Cellular Neuroscience, 13, 472800.

  15. Shadrina, M., et al. (2010). Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. Journal of Molecular Neuroscience, 41(1), 30-35.

  16. Tsai, S. (2007). Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome. Medical Hypotheses, 68(5), 1144-1146.

  17. Dolotov, O. V., et al. (2006). Semax, an analog of ACTH (4–10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54-60.

  18. Gao, N., et al. (2022). Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential. Translational Neurodegeneration, 11, 4.

  19. Liu, W., et al. (2020). Brain-derived neurotrophic factor and its potential therapeutic role in stroke comorbidities. Neural Plasticity, 2020, 1969482.

  20. Oh, H., Lewis, D. A., & Sibille, E. (2016). The role of BDNF in age-dependent changes of excitatory and inhibitory synaptic markers in the human prefrontal cortex. Neuropsychopharmacology, 41(13), 3080-3091.

  21. Gusev, E. I., et al. (1997). Effectiveness of semax in acute period of hemispheric ischemic stroke (A clinical and electrophysiological study). Zhurnal nevrologii i psikhiatrii imeni SS Korsakova, 97(6), 26-34.

  22. Lebedeva, I. S., et al. (2018). Effects of Semax on the default mode network of the brain. Bulletin of Experimental Biology and Medicine, 165(5), 653-656.

  23. National Institute of Aging. (2024). What happens to the brain in Alzheimer's disease? NIA.

  24. UCLA Health. (2021). How do brain cells compensate for damage from a stroke? UCLA Health.

  25. Suliman, S., J Hemmings, S. M., & Seedat, S. (2013). Brain-derived neurotrophic factor (BDNF) protein levels in anxiety disorders: Systematic review and meta-regression analysis. Frontiers in Integrative Neuroscience, 7, 55.

  26. Correia, A. S., Cardoso, A., & Vale, N. (2023). BDNF unveiled: Exploring its role in major depression disorder, serotonergic imbalance, and associated stress conditions. Pharmaceutics, 15(8), 2081.

  27. Inozemtseva, L. S., et al. (2024). Antidepressant-like and antistress effects of the ACTH(4–10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. European Journal of Pharmacology, 984, 177068.

  28. Levitskaya, N. G., et al. (2010). Influence of Semax on the emotional state of white rats in the norm and against the background of cholecystokinin-tetrapeptide action. Biology Bulletin, 37, 186-192.

  29. Koroleva, S. V., & Myasoedov, N. F. (2019). Semax as a universal drug for therapy and research. Biology Bulletin, 45, 589-600.

  30. Medvedeva, E. K., et al. (2017). Semax, an analog of ACTH (4−7), regulates expression of immune response genes during ischemic brain injury in rats. Molecular Genetics and Genomics, 292, 635-653.

  31. Manchenko, D. M., et al. (2010). Nootropic and analgesic effects of Semax following different routes of administration. Rossiiskii fiziologicheskii zhurnal imeni IM Sechenova, 96(10), 1014-1023.

  32. Golubeva, A.V., et al. (2006). Protective effect of peptide Semax on the rat heart in acute myocardial infarction. Rossiiskii fiziologicheskii zhurnal imeni IM Sechenova, 92(6), 732-845.

  33. Zhuikova, S. E., et al. (2002). Possible mechanism underlying the effect of Semax on the formation of indomethacin-induced ulcers in rats. Bulletin of Experimental Biology and Medicine, 133(6), 577-579.

  34. Deigin, V. I., et al. (2022). Development of peptide biopharmaceuticals in Russia. Pharmaceutics, 14(4), 716.

  35. De Groot, A. S., et al. (2023). Immunogenicity risk assessment of synthetic peptide drugs and their impurities. Drug Discovery Today, 28(10), 103714.

  36. U.S. Food & Drug Administration. (2024). Certain bulk drug substances for use in compounding that may present significant safety risks. FDA.

  37. National Institute for Biological Standards and Control. (n.d.). Peptide handling, dissolution & storage. NIBSC.

  38. Kaplan, A., et al. (1996). Synthetic ACTH analogue Semax displays nootropic‐like activity in humans. Neuroscience Research Communications, 19(2), 115-123.